| 8 July 2008 | Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
|
| 4 June 2008 | Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis
|
| 27 November 2007 | Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan
|
| 29 October 2007 | Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
|
| 6 March 2007 | Amarin Expands Neurology Pipeline With Epilepsy Product Candidate
|
| 5 Sept 2006 | ADDITIONAL NANOCRYSTAL® TECHNOLOGY PATENT ISSUED COVERING PAR’S MEGACE ®ES
|
| 6 Jul 2006 | Elan Signs License Agreement with Abbott for Elan's Proprietary NanoCrystal(R) Technology; To Develop a Single Fixed-Dose Combination of TriCor(R) and Crestor(R) for High Cholesterol Patients
|
| 10 Jan 2006 | Elan and EntreMed Execute License Agreement for Proprietary NanoCrystal® Technology
|
| 27 July 2005 | MAP Pharmaceuticals Announce Expanded Development Agreement With Elan Drug Technologies Proprietary Elan NanoCrystal® Technology to be Applied to MAP’s Novel Asthma Therapeutics
|
| 06 July 2005 | Par Pharmaceutical Announces FDA Approval of Megace(R) ES for Anorexia, Cachexia, or an Unexplained, Significant Weight Loss in Patients With a Diagnosis of AIDS
|
| 07 Feb 2005 | Japanese Patent Office Issues Patent Certificate to Elan for Its NanoCrystal-TM- Technology
|
| 12 Jan 2005 | Elan's Proprietary NanoCrystal® Technology is Used by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&J PRD) in Phase III Clinical Trial of Paliperidone Palmitate
|
| 07 Jan 2005 | Elan and Roche Expand Nanocrystal Technology License
|
| 14 Jun 2004 | Announcement on the establishment of new Sterile Biopharmaceuticals Plant at its Athlone, Ireland facility
|
| 10 Jun 2004 | Elan Announces Manufacturing Agreement with Lilly
|
| 21 Apr 2004 | Elan NanoSystems licenses NanoCrystal™ technology to Roche
|
| 20 Jan 2004 | Elan NanoSystems licenses NanoCrystal™ technology to Aventis
|
| 13 Oct 2003 | Elan's NanoSystems licenses NanoCrystal® to Janssen
|
| 30 Sep 2003 | Elan's NanoSystems and Bristol-Myers Squibb sign license
|
| 20 May 2003 | Merck and Elan Announce NanoCrystal® Technology is Formulation for Merck’s Emend® (aprepitant)
|
| 30 Aug 2000 | Elan announces first U.S. approval for its NanoCrystal™ technology
|
| |
